{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T01:02:43Z","timestamp":1789434163015,"version":"build-2803163510"},"reference-count":126,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T00:00:00Z","timestamp":1782604800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":79,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-026-02222-3","type":"journal-article","created":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T04:25:32Z","timestamp":1782620732000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Harnessing the gut microbiome for improved immune checkpoint inhibition in colorectal cancer immunotherapy: a narrative Review"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-7787-8961","authenticated-orcid":false,"given":"Desalegn","family":"Abebaw","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adane","family":"Adugna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bantayehu Addis","family":"Tegegne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zigale Hibstu","family":"Teffera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bantegzie","family":"Selabat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonatan","family":"Kindie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melkamu","family":"Tilahun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Habtamu","family":"Belew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Temesgen","family":"Baylie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Getachew","family":"Mengistu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Jemal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aytenew","family":"Atnaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,28]]},"reference":[{"issue":"1","key":"2222_CR1","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.gtc.2020.10.012","volume":"50","author":"E Zhou","year":"2021","unstructured":"Zhou E, Rifkin S. Colorectal Cancer and Diet: Risk Versus Prevention, Is Diet an Intervention? Gastroenterol Clin North Am. 2021;50(1):101\u201311.","journal-title":"Gastroenterol Clin North Am"},{"issue":"2","key":"2222_CR2","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s10555-023-10158-3","volume":"43","author":"R Abedizadeh","year":"2024","unstructured":"Abedizadeh R, et al. Colorectal cancer: a comprehensive review of carcinogenesis, diagnosis, and novel strategies for classified treatments. Cancer Metastasis Rev. 2024;43(2):729\u201353.","journal-title":"Cancer Metastasis Rev"},{"issue":"7","key":"2222_CR3","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1001\/jama.2021.0106","volume":"325","author":"LH Biller","year":"2021","unstructured":"Biller LH, Schrag D. Diagnosis and Treatment of Metastatic Colorectal Cancer: A Review. JAMA. 2021;325(7):669\u201385.","journal-title":"JAMA"},{"issue":"3","key":"2222_CR4","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/S2468-1253(21)00426-X","volume":"7","author":"SG Patel","year":"2022","unstructured":"Patel SG, et al. The rising tide of early-onset colorectal cancer: a comprehensive review of epidemiology, clinical features, biology, risk factors, prevention, and early detection. Lancet Gastroenterol Hepatol. 2022;7(3):262\u201374.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2222_CR5","unstructured":"Copur MS. Immunotherapy in Colorectal Cancer. Oncol (Williston Park), 2019;33(10):686506."},{"issue":"1","key":"2222_CR6","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1186\/s13287-022-02913-0","volume":"13","author":"H Zheng","year":"2022","unstructured":"Zheng H, et al. Characterization of stem cell landscape and identification of stemness-relevant prognostic gene signature to aid immunotherapy in colorectal cancer. Stem Cell Res Ther. 2022;13(1):244.","journal-title":"Stem Cell Res Ther"},{"key":"2222_CR7","doi-asserted-by":"crossref","unstructured":"Ahmad R et al. Emerging trends in colorectal cancer: Dysregulated signaling pathways (Review). Int J Mol Med, 2021;47(3):14.","DOI":"10.3892\/ijmm.2021.4847"},{"issue":"1","key":"2222_CR8","first-page":"1798","volume":"13","author":"CD Gatenbee","year":"2022","unstructured":"Gatenbee CD, Baker AM. Immunosuppressive niche Eng onset Hum colorectal cancer. 2022;13(1):1798.","journal-title":"Immunosuppressive niche Eng onset Hum colorectal cancer"},{"issue":"8","key":"2222_CR9","doi-asserted-by":"publisher","first-page":"617","DOI":"10.2174\/1568009622666220224110912","volume":"22","author":"VS Silva","year":"2022","unstructured":"Silva VS, et al. The Current and Evolving Role of Immunotherapy in Metastatic Colorectal Cancer. Curr Cancer Drug Targets. 2022;22(8):617\u201328.","journal-title":"Curr Cancer Drug Targets"},{"key":"2222_CR10","doi-asserted-by":"publisher","first-page":"1433315","DOI":"10.3389\/fimmu.2024.1433315","volume":"15","author":"B Yu","year":"2024","unstructured":"Yu B, et al. Immunotherapy for colorectal cancer. Front Immunol. 2024;15:1433315.","journal-title":"Front Immunol"},{"key":"2222_CR11","doi-asserted-by":"publisher","first-page":"1410928","DOI":"10.3389\/fimmu.2024.1410928","volume":"15","author":"Y Xie","year":"2024","unstructured":"Xie Y, Liu F. The role of the gut microbiota in tumor, immunity, and immunotherapy. Front Immunol. 2024;15:1410928.","journal-title":"Front Immunol"},{"key":"2222_CR12","doi-asserted-by":"publisher","first-page":"892512","DOI":"10.3389\/fimmu.2022.892512","volume":"13","author":"Y Hou","year":"2022","unstructured":"Hou Y, et al. Comprehensive Analysis of a Cancer-Immunity Cycle-Based Signature for Predicting Prognosis and Immunotherapy Response in Patients With Colorectal Cancer. Front Immunol. 2022;13:892512.","journal-title":"Front Immunol"},{"key":"2222_CR13","doi-asserted-by":"crossref","unstructured":"Zeng T et al. Efficacy and safety of immune checkpoint inhibitors in colorectal cancer: a systematic review and meta-analysis. 2022. 37(1): pp. 251\u2013258.","DOI":"10.1007\/s00384-021-04028-z"},{"issue":"1","key":"2222_CR14","doi-asserted-by":"publisher","first-page":"101355","DOI":"10.1016\/j.xcrm.2023.101355","volume":"5","author":"S Cheng","year":"2024","unstructured":"Cheng S, et al. Multi-omics of the gut microbial ecosystem in patients with microsatellite-instability-high gastrointestinal cancer resistant to immunotherapy. Cell Rep Med. 2024;5(1):101355.","journal-title":"Cell Rep Med"},{"issue":"14","key":"2222_CR15","doi-asserted-by":"publisher","first-page":"3837","DOI":"10.7150\/ijbs.64077","volume":"17","author":"A Fan","year":"2021","unstructured":"Fan A, et al. Immunotherapy in colorectal cancer: current achievements and future perspective. Int J Biol Sci. 2021;17(14):3837\u201349.","journal-title":"Int J Biol Sci"},{"issue":"5","key":"2222_CR16","first-page":"e580","volume":"29","author":"DC Guven","year":"2024","unstructured":"Guven DC, Kavgaci G, Erul E. The Efficacy of Immune Checkpoint Inhibitors in Microsatellite Stable Colorectal Cancer. Syst Rev. 2024;29(5):e580\u2013600.","journal-title":"Syst Rev"},{"issue":"1","key":"2222_CR17","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s11523-019-00690-0","volume":"15","author":"R Cohen","year":"2020","unstructured":"Cohen R, et al. Immune Checkpoint Inhibition in Colorectal Cancer: Microsatellite Instability and Beyond. Target Oncol. 2020;15(1):11\u201324.","journal-title":"Target Oncol"},{"key":"2222_CR18","doi-asserted-by":"publisher","first-page":"104775","DOI":"10.1016\/j.critrevonc.2025.104775","volume":"212","author":"E Chen","year":"2025","unstructured":"Chen E, Zhou W. Immunotherapy in microsatellite-stable colorectal cancer: Strategies to overcome resistance. Crit Rev Oncol Hematol. 2025;212:104775.","journal-title":"Crit Rev Oncol Hematol"},{"key":"2222_CR19","doi-asserted-by":"crossref","unstructured":"Cao Y et al. Colorectal cancer-associated T cell receptor repertoire abnormalities are linked to gut microbiome shifts and somatic cell mutations. 2023. 15(2): p. 2263934.","DOI":"10.1080\/19490976.2023.2263934"},{"issue":"7","key":"2222_CR20","first-page":"1007","volume":"31","author":"J Chen","year":"2024","unstructured":"Chen J, Singh N, Ye X. Gut microbiota-mediated activation GSDMD ignites colorectal tumorigenesis. 2024;31(7):1007\u201317.","journal-title":"Gut microbiota-mediated activation GSDMD ignites colorectal tumorigenesis"},{"key":"2222_CR21","doi-asserted-by":"crossref","unstructured":"Pramana AAC, Xu GB. Gut microbiota dysbiosis in a novel mouse model of colitis potentially increases the risk of colorectal cancer. Am J Physiol Gastrointest Liver Physiol. 2025. 328(6): pp. G831\u201347.","DOI":"10.1152\/ajpgi.00040.2025"},{"key":"2222_CR22","doi-asserted-by":"crossref","unstructured":"Deng J et al. Fusobacterium mortiferum and its metabolite 5-aminovaleric acid promote the development of colorectal cancer in obese individuals through Wnt\/\u03b2-catenin pathway by DKK2. Gut Microbes. 2025;17(1):2502138.","DOI":"10.1080\/19490976.2025.2502138"},{"issue":"4","key":"2222_CR23","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1136\/gutjnl-2015-309595","volume":"66","author":"B Flemer","year":"2017","unstructured":"Flemer B, et al. Tumour-associated and non-tumour-associated microbiota in colorectal cancer. Gut. 2017;66(4):633\u201343.","journal-title":"Gut"},{"key":"2222_CR24","doi-asserted-by":"crossref","unstructured":"Kong C et al. Integrated metagenomic and metabolomic analysis reveals distinct gut-microbiome-derived phenotypes in early-onset colorectal cancer. Gut. 2023;72(6):1129\u201342.","DOI":"10.1136\/gutjnl-2022-327156"},{"issue":"4","key":"2222_CR25","doi-asserted-by":"publisher","first-page":"529","DOI":"10.3233\/CBM-201606","volume":"28","author":"H Pi","year":"2020","unstructured":"Pi H, et al. Effects of PD-1\/PD-L1 signaling pathway on intestinal flora in patients with colorectal cancer. Cancer Biomark. 2020;28(4):529\u201335.","journal-title":"Cancer Biomark"},{"key":"2222_CR26","doi-asserted-by":"crossref","unstructured":"Hale VL et al. Distinct microbes, metabolites, and ecologies define the microbiome in deficient and proficient mismatch repair colorectal cancers. Genome Med. 2018;10(1):78.","DOI":"10.1186\/s13073-018-0586-6"},{"key":"2222_CR27","doi-asserted-by":"publisher","first-page":"993285","DOI":"10.3389\/fmicb.2022.993285","volume":"13","author":"M Jin","year":"2022","unstructured":"Jin M, et al. Gut microbiota distinct between colorectal cancers with deficient and proficient mismatch repair: A study of 230 CRC patients. Front Microbiol. 2022;13:993285.","journal-title":"Front Microbiol"},{"key":"2222_CR28","doi-asserted-by":"crossref","unstructured":"Galeano Ni\u00f1o JL et al. Effect of the intratumoral microbiota on spatial and cellular heterogeneity in cancer. Nature. 2022;611(7937):810\u2013817.","DOI":"10.1038\/s41586-022-05435-0"},{"key":"2222_CR29","doi-asserted-by":"publisher","first-page":"1051987","DOI":"10.3389\/fimmu.2022.1051987","volume":"13","author":"F Gao","year":"2022","unstructured":"Gao F, et al. The effect of the intratumoral microbiome on tumor occurrence, progression, prognosis and treatment. Front Immunol. 2022;13:1051987.","journal-title":"Front Immunol"},{"issue":"1","key":"2222_CR30","doi-asserted-by":"publisher","first-page":"2323861","DOI":"10.1080\/21645515.2024.2323861","volume":"20","author":"QL Ou","year":"2024","unstructured":"Ou QL, et al. Mapping the intellectual structure and landscape of colorectal cancer immunotherapy: A bibliometric analysis. Hum Vaccin Immunother. 2024;20(1):2323861.","journal-title":"Hum Vaccin Immunother"},{"key":"2222_CR31","doi-asserted-by":"publisher","first-page":"814","DOI":"10.3389\/fmicb.2020.00814","volume":"11","author":"X Xu","year":"2020","unstructured":"Xu X, et al. Gut Microbiome Influences the Efficacy of PD-1 Antibody Immunotherapy on MSS-Type Colorectal Cancer via Metabolic Pathway. Front Microbiol. 2020;11:814.","journal-title":"Front Microbiol"},{"key":"2222_CR32","doi-asserted-by":"crossref","unstructured":"Wang S et al. The role of intestinal flora on tumorigenesis, progression, and the efficacy of PD-1\/PD-L1 antibodies in colorectal cancer. Cancer Biol Med. 2023;21(1):65\u201382.","DOI":"10.20892\/j.issn.2095-3941.2023.0376"},{"key":"2222_CR33","doi-asserted-by":"crossref","unstructured":"Temraz S et al. Gut Microbiome: Promis Biomark Immunotherapy Colorectal Cancer 2019;20(17):4155.","DOI":"10.3390\/ijms20174155"},{"key":"2222_CR34","doi-asserted-by":"publisher","first-page":"104629","DOI":"10.1016\/j.critrevonc.2025.104629","volume":"208","author":"Y Chang","year":"2025","unstructured":"Chang Y, et al. Combining gut microbiota modulation and immunotherapy: A promising approach for treating microsatellite stable colorectal cancer. Crit Rev Oncol Hematol. 2025;208:104629.","journal-title":"Crit Rev Oncol Hematol"},{"key":"2222_CR35","doi-asserted-by":"crossref","unstructured":"Su X et al. Tumor-suppressing multi-enterobacteria enhance the anti-PD-1\/PD-L1 efficacy in microsatellite stable colorectal cancer. Sci Rep, 2026;16(1):14069.","DOI":"10.1038\/s41598-026-44494-5"},{"key":"2222_CR36","doi-asserted-by":"crossref","unstructured":"Cao M et al. Single-cell transcriptomic analysis reveals gut microbiota-immunotherapy synergy through modulating tumor microenvironment. . 2025;10(1):140.","DOI":"10.1038\/s41392-025-02226-7"},{"issue":"12","key":"2222_CR37","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.15537\/smj.2022.43.12.20220367","volume":"43","author":"GA Alasiri","year":"2022","unstructured":"Alasiri GA. Effect of gut microbiota on colorectal cancer progression and treatment. Saudi Med J. 2022;43(12):1289\u201399.","journal-title":"Saudi Med J"},{"key":"2222_CR38","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1146\/annurev-physiol-042022-025619","volume":"86","author":"G El Tekle","year":"2024","unstructured":"El Tekle G, Andreeva N, Garrett WS. The Role of the Microbiome in the Etiopathogenesis of Colon Cancer. Annu Rev Physiol. 2024;86:453\u201378.","journal-title":"Annu Rev Physiol"},{"issue":"1","key":"2222_CR39","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1186\/s12967-023-04119-1","volume":"21","author":"J Liu","year":"2023","unstructured":"Liu J, et al. Identification of colorectal cancer progression-associated intestinal microbiome and predictive signature construction. J Transl Med. 2023;21(1):373.","journal-title":"J Transl Med"},{"issue":"1","key":"2222_CR40","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.cmet.2022.11.013","volume":"35","author":"HN Bell","year":"2023","unstructured":"Bell HN, et al. Microenvironmental ammonia enhances T cell exhaustion in colorectal cancer. Cell Metab. 2023;35(1):134\u2013e1496.","journal-title":"Cell Metab"},{"key":"2222_CR41","doi-asserted-by":"crossref","unstructured":"Avuthu N, Guda C. Meta-Analysis of Altered Gut Microbiota Reveals Microbial and Metabolic Biomarkers for Colorectal Cancer. Microbiol Spectr. 2022;10(4):e0001322.","DOI":"10.1128\/spectrum.00013-22"},{"key":"2222_CR42","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/bs.adgen.2024.06.001","volume":"112","author":"A Gonz\u00e1lez","year":"2024","unstructured":"Gonz\u00e1lez A, et al. Microbiota and detrimental protein derived metabolites in colorectal cancer. Adv Genet. 2024;112:255\u2013308.","journal-title":"Adv Genet"},{"key":"2222_CR43","doi-asserted-by":"publisher","first-page":"1008975","DOI":"10.3389\/fimmu.2022.1008975","volume":"13","author":"Z Xu","year":"2022","unstructured":"Xu Z, et al. Dysbiosis of human tumor microbiome and aberrant residence of Actinomyces in tumor-associated fibroblasts in young-onset colorectal cancer. Front Immunol. 2022;13:1008975.","journal-title":"Front Immunol"},{"key":"2222_CR44","doi-asserted-by":"crossref","unstructured":"Sun Y et al. Lactobacillus intestinalis facilitates tumor-derived CCL5 to recruit dendritic cell and suppress colorectal tumorigenesis. Gut Microbes. 2025;17(1):2449111.","DOI":"10.1080\/19490976.2024.2449111"},{"key":"2222_CR45","doi-asserted-by":"crossref","unstructured":"Cremonesi E et al. Gut microbiota modulate T cell trafficking into human colorectal cancer. Gut. 2018;67(11):1984\u201394.","DOI":"10.1136\/gutjnl-2016-313498"},{"key":"2222_CR46","doi-asserted-by":"crossref","unstructured":"Long X et al. Peptostreptococcus anaerobius promotes colorectal carcinogenesis and modulates tumour immunity. Nat Microbiol. 2019;4(12):2319\u201330.","DOI":"10.1038\/s41564-019-0541-3"},{"key":"2222_CR47","doi-asserted-by":"crossref","unstructured":"D\u00edaz-Basabe A et al. Porphyromonas gingivalis fuels colorectal cancer through CHI3L1-mediated iNKT cell-driven immune evasion. Gut Microbes. 2024;6(1):2388801.","DOI":"10.1080\/19490976.2024.2388801"},{"key":"2222_CR48","doi-asserted-by":"crossref","unstructured":"Lattanzi G et al. Estrogen-related differences in antitumor immunity and gut microbiome contribute to sexual dimorphism of colorectal cancer. Oncoimmunology. 2024;13(1):2425125.","DOI":"10.1080\/2162402X.2024.2425125"},{"key":"2222_CR49","doi-asserted-by":"crossref","unstructured":"Kvich L, Fritz BG. Biofilms and core pathogens shape the tumor microenvironment and immune phenotype in colorectal cancer. Gut Microbes. 2024;16(1):2350156.","DOI":"10.1080\/19490976.2024.2350156"},{"key":"2222_CR50","doi-asserted-by":"crossref","unstructured":"Lee YK et al. The Protective Role of Bacteroides fragilis in a Murine Model of Colitis-Associated Colorectal Cancer. mSphere, 2018;3(6):e00587-18.","DOI":"10.1128\/mSphere.00587-18"},{"key":"2222_CR51","doi-asserted-by":"crossref","unstructured":"Dai Z et al. Multi-cohort analysis of colorectal cancer metagenome identified altered bacteria across populations and universal bacterial markers. Microbiome. 2018;6(1):70.","DOI":"10.1186\/s40168-018-0451-2"},{"key":"2222_CR52","doi-asserted-by":"crossref","unstructured":"Coker OO et al. Altered gut metabolites and microbiota interactions are implicated in colorectal carcinogenesis and can be non-invasive diagnostic biomarkers. Microbiome. 2022;10(1):35.","DOI":"10.1186\/s40168-021-01208-5"},{"key":"2222_CR53","doi-asserted-by":"publisher","first-page":"657867","DOI":"10.3389\/fcimb.2021.657867","volume":"11","author":"R Gao","year":"2021","unstructured":"Gao R, et al. Alterations, Interactions, and Diagnostic Potential of Gut Bacteria and Viruses in Colorectal Cancer. Front Cell Infect Microbiol. 2021;11:657867.","journal-title":"Front Cell Infect Microbiol"},{"key":"2222_CR54","doi-asserted-by":"crossref","unstructured":"Zhou Q, Lei L. Microbiota-induced S100A11-RAGE axis underlies immune evasion in right-sided colon adenomas and is a therapeutic target to boost anti-PD1 efficacy. Gut. 2025;74(2):214\u201328.","DOI":"10.1136\/gutjnl-2024-332193"},{"issue":"4","key":"2222_CR55","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/j.immuni.2024.02.014","volume":"57","author":"J Cong","year":"2024","unstructured":"Cong J, et al. Bile acids modified by the intestinal microbiota promote colorectal cancer growth by suppressing CD8(+) T cell effector functions. Immunity. 2024;57(4):876\u2013e88911.","journal-title":"Immunity"},{"key":"2222_CR56","doi-asserted-by":"crossref","unstructured":"Liao Q et al. Gut microbial metabolite 4-hydroxybenzeneacetic acid drives colorectal cancer progression via accumulation of immunosuppressive PMN-MDSCs. J Clin Invest, 2025;135(11):e181243.","DOI":"10.1172\/JCI181243"},{"key":"2222_CR57","doi-asserted-by":"publisher","first-page":"114283","DOI":"10.1016\/j.intimp.2025.114283","volume":"150","author":"Y Chen","year":"2025","unstructured":"Chen Y, et al. Bifidobacterium longum subsp. longum XZ01 delays the progression of colon cancer in mice through the interaction between the microbial spatial distribution and tumour immunity. Int Immunopharmacol. 2025;150:114283.","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"2222_CR58","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1007\/s10565-024-09889-y","volume":"40","author":"X Nie","year":"2024","unstructured":"Nie X, et al. Novel therapeutic targets: bifidobacterium-mediated urea cycle regulation in colorectal cancer. Cell Biol Toxicol. 2024;40(1):64.","journal-title":"Cell Biol Toxicol"},{"key":"2222_CR59","doi-asserted-by":"crossref","unstructured":"Kang X et al. Roseburia intestinalis generated butyrate boosts anti-PD-1 efficacy in colorectal cancer by activating cytotoxic CD8(+) T cells. Gut. 2023;72(11):2112\u201322.","DOI":"10.1136\/gutjnl-2023-330291"},{"issue":"4","key":"2222_CR60","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1053\/j.gastro.2016.11.018","volume":"152","author":"Y Yang","year":"2017","unstructured":"Yang Y, et al. Fusobacterium nucleatum Increases Proliferation of Colorectal Cancer Cells and Tumor Development in Mice by Activating Toll-Like Receptor 4 Signaling to Nuclear Factor-\u03baB, and Up-regulating Expression of MicroRNA-21. Gastroenterology. 2017;152(4):851\u2013e86624.","journal-title":"Gastroenterology"},{"issue":"1","key":"2222_CR61","doi-asserted-by":"publisher","first-page":"2046246","DOI":"10.1080\/19490976.2022.2046246","volume":"14","author":"SL Zhang","year":"2022","unstructured":"Zhang SL, et al. Lacticaseibacillus paracasei sh2020 induced antitumor immunity and synergized with anti-programmed cell death 1 to reduce tumor burden in mice. Gut Microbes. 2022;14(1):2046246.","journal-title":"Gut Microbes"},{"issue":"8","key":"2222_CR62","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.4014\/jmb.2404.04055","volume":"34","author":"IH Tae","year":"2024","unstructured":"Tae IH, et al. Induction of Cell Death by Bifidobacterium infantis DS1685 in Colorectal and Breast Cancers via SMAD4\/TGF-Beta Activation. J Microbiol Biotechnol. 2024;34(8):1698\u2013704.","journal-title":"J Microbiol Biotechnol"},{"issue":"1","key":"2222_CR63","doi-asserted-by":"publisher","first-page":"20128","DOI":"10.1038\/s41598-019-56661-y","volume":"9","author":"Q Zhuo","year":"2019","unstructured":"Zhuo Q, et al. Lysates of Lactobacillus acidophilus combined with CTLA-4-blocking antibodies enhance antitumor immunity in a mouse colon cancer model. Sci Rep. 2019;9(1):20128.","journal-title":"Sci Rep"},{"issue":"8","key":"2222_CR64","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/nrgastro.2014.66","volume":"11","author":"C Hill","year":"2014","unstructured":"Hill C, et al. Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 2014;11(8):506\u201314.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"12","key":"2222_CR65","first-page":"1050","volume":"76","author":"S Zuo","year":"2024","unstructured":"Zuo S, Huang Y, Zou J. role gut microbiome modulating immunotherapy efficacy colorectal cancer. IUBMB Life. 2024;76(12):1050\u20137.","journal-title":"role gut microbiome modulating immunotherapy efficacy colorectal cancer"},{"key":"2222_CR66","doi-asserted-by":"crossref","unstructured":"Huang F, Li S. Postoperative Probiotics Administration Attenuates Gastrointestinal Complications and Gut Microbiota Dysbiosis Caused by Chemotherapy in Colorectal Cancer Patients. Nutrients. 2023;15(2):356.","DOI":"10.3390\/nu15020356"},{"key":"2222_CR67","doi-asserted-by":"publisher","first-page":"123233","DOI":"10.1016\/j.biomaterials.2025.123233","volume":"320","author":"S Li","year":"2025","unstructured":"Li S, et al. Overcoming immunotherapy resistance in colorectal cancer through nano-selenium probiotic complexes and IL-32 modulation. Biomaterials. 2025;320:123233.","journal-title":"Biomaterials"},{"key":"2222_CR68","doi-asserted-by":"crossref","unstructured":"Wang J et al. Targeting the Adenosine-Mediated Metabolic Immune Checkpoint with Engineered Probiotic for Enhanced Chemo-Immunotherapy. Adv Sci (Weinh). 2025;12(15):e2411813.","DOI":"10.1002\/advs.202411813"},{"key":"2222_CR69","doi-asserted-by":"publisher","first-page":"123810","DOI":"10.1016\/j.ijpharm.2024.123810","volume":"652","author":"L Niu","year":"2024","unstructured":"Niu L, et al. Oral probiotics microgel plus Galunisertib reduced TGF-\u03b2 blockade resistance and enhanced anti-tumor immune responses in colorectal cancer. Int J Pharm. 2024;652:123810.","journal-title":"Int J Pharm"},{"key":"2222_CR70","doi-asserted-by":"crossref","unstructured":"Lu S et al. Dietary Lactobacillus rhamnosus GG extracellular vesicles enhance antiprogrammed cell death 1 (anti-PD-1) immunotherapy efficacy against colorectal cancer. Food Funct. 2023;14(23):10314\u201328.","DOI":"10.1039\/D3FO02018E"},{"issue":"4","key":"2222_CR71","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1016\/j.jcmgh.2021.06.001","volume":"12","author":"JA Owens","year":"2021","unstructured":"Owens JA, et al. Lactobacillus rhamnosus GG Orchestrates an Antitumor Immune Response. Cell Mol Gastroenterol Hepatol. Gut Microbes. 2021;12(4):1311\u201327.","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"2222_CR72","doi-asserted-by":"crossref","unstructured":"Lee PJ et al. MS-20 enhances the gut microbiota-associated antitumor effects of anti-PD1 antibody. Gut Microbes. 2024;16(1):2380061.","DOI":"10.1080\/19490976.2024.2380061"},{"issue":"12","key":"2222_CR73","doi-asserted-by":"publisher","first-page":"3746","DOI":"10.1016\/j.bbadis.2018.10.006","volume":"1864","author":"C Howe","year":"2018","unstructured":"Howe C, et al. Differential expression of tumor-associated genes and altered gut microbiome with decreased Akkermansia muciniphila confer a tumor-preventive microenvironment in intestinal epithelial Pten-deficient mice. Biochim Biophys Acta Mol Basis Dis. 2018;1864(12):3746\u201358.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"1","key":"2222_CR74","doi-asserted-by":"publisher","first-page":"15250","DOI":"10.1038\/s41598-020-72132-1","volume":"10","author":"T L\u00f6wenmark","year":"2020","unstructured":"L\u00f6wenmark T, et al. Parvimonas micra as a putative non-invasive faecal biomarker for colorectal cancer. Sci Rep. 2020;10(1):15250.","journal-title":"Sci Rep"},{"issue":"1","key":"2222_CR75","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s13099-022-00527-8","volume":"14","author":"H Chen","year":"2022","unstructured":"Chen H, et al. Metagenomic analysis of the interaction between the gut microbiota and colorectal cancer: a paired-sample study based on the GMrepo database. Gut Pathog. 2022;14(1):48.","journal-title":"Gut Pathog"},{"issue":"2","key":"2222_CR76","doi-asserted-by":"publisher","first-page":"47","DOI":"10.4291\/wjgp.v9.i2.47","volume":"9","author":"L Farhana","year":"2018","unstructured":"Farhana L, et al. Gut microbiome profiling and colorectal cancer in African Americans and Caucasian Americans. World J Gastrointest Pathophysiol. 2018;9(2):47\u201358.","journal-title":"World J Gastrointest Pathophysiol"},{"issue":"14","key":"2222_CR77","doi-asserted-by":"publisher","first-page":"4393","DOI":"10.7150\/ijbs.85712","volume":"19","author":"L Zhang","year":"2023","unstructured":"Zhang L, et al. Akkermansia muciniphila inhibits tryptophan metabolism via the AhR\/\u03b2-catenin signaling pathway to counter the progression of colorectal cancer. Int J Biol Sci. 2023;19(14):4393\u2013410.","journal-title":"Int J Biol Sci"},{"key":"2222_CR78","doi-asserted-by":"crossref","unstructured":"Hua D et al. The combination of Clostridium butyricum and Akkermansia muciniphila mitigates DSS-induced colitis and attenuates colitis-associated tumorigenesis by modulating gut microbiota and reducing CD8(+) T cells in mice. mSystems. 2025;10(2):e0156724.","DOI":"10.1128\/msystems.01567-24"},{"issue":"1","key":"2222_CR79","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s12876-025-03604-9","volume":"25","author":"X Wang","year":"2025","unstructured":"Wang X, et al. Effect of probiotics combined with immune checkpoint suppressors and chemotherapeutic agents on digestive system function, intestinal immunity and prognosis in patients with metastatic colorectal carcinoma: a quasi-experimental study. BMC Gastroenterol. 2025;25(1):38.","journal-title":"BMC Gastroenterol"},{"issue":"1","key":"2222_CR80","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1007\/s12672-025-01996-4","volume":"16","author":"DS Morsli","year":"2025","unstructured":"Morsli DS, et al. Probiotics in colorectal cancer prevention and therapy: mechanisms, benefits, and challenges. Discov Oncol. 2025;16(1):406.","journal-title":"Discov Oncol"},{"key":"2222_CR81","doi-asserted-by":"crossref","unstructured":"Li B, Pan LL. Novel Probiotic Lactic Acid Bacteria Were Identified from Healthy Infant Feces and Exhibited Anti-Inflammatory Capacities. Antioxidants (Basel). 2022;11(7):1246.","DOI":"10.3390\/antiox11071246"},{"key":"2222_CR82","doi-asserted-by":"crossref","unstructured":"Fong W et al. Lactobacillus gallinarum-derived metabolites boost anti-PD1 efficacy in colorectal cancer by inhibiting regulatory T cells through modulating IDO1\/Kyn\/AHR axis. Gut. 2023;72(12):2272\u201385.","DOI":"10.1136\/gutjnl-2023-329543"},{"key":"2222_CR83","doi-asserted-by":"crossref","unstructured":"Xu H et al. Therapeutic potential of Clostridium butyricum anticancer effects in colorectal cancer. Gut Microbes. 2023;15(1):2186114.","DOI":"10.1080\/19490976.2023.2186114"},{"key":"2222_CR84","doi-asserted-by":"crossref","unstructured":"Si W et al. Lactobacillus rhamnosus GG induces cGAS\/STING- dependent type I interferon and improves response to immune checkpoint blockade. Gut. 2022;71(3):521\u201333.","DOI":"10.1136\/gutjnl-2020-323426"},{"key":"2222_CR85","doi-asserted-by":"publisher","first-page":"104533","DOI":"10.1016\/j.ebiom.2023.104533","volume":"91","author":"G Gao","year":"2023","unstructured":"Gao G, et al. Lacticaseibacillus rhamnosus Probio-M9 enhanced the antitumor response to anti-PD-1 therapy by modulating intestinal metabolites. EBioMedicine. 2023;91:104533.","journal-title":"EBioMedicine"},{"issue":"6","key":"2222_CR86","doi-asserted-by":"publisher","first-page":"167891","DOI":"10.1016\/j.bbadis.2025.167891","volume":"1871","author":"J Xin","year":"2025","unstructured":"Xin J, et al. Next-generation probiotics Alistipes onderdonkii enhances the efficacy of anti-PD-1 therapy in colorectal cancer. Biochim Biophys Acta Mol Basis Dis. 2025;1871(6):167891.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"2222_CR87","doi-asserted-by":"crossref","unstructured":"Shi L, Sheng J. Combining IL-2-based immunotherapy with commensal probiotics produces enhanced antitumor immune response and tumor clearance. J Immunother Canc. 2020;8(2):e000973.","DOI":"10.1136\/jitc-2020-000973"},{"key":"2222_CR88","doi-asserted-by":"crossref","unstructured":"Nicco C et al. From Donor to Patient: Collection, Preparation and Cryopreservation of Fecal Samples for Fecal Microbiota Transplantation. Diseases, 2020;8(2):9.","DOI":"10.3390\/diseases8020009"},{"key":"2222_CR89","doi-asserted-by":"publisher","first-page":"874922","DOI":"10.3389\/fimmu.2022.874922","volume":"13","author":"J Huang","year":"2022","unstructured":"Huang J, et al. Metagenomic and metabolomic analyses reveal synergistic effects of fecal microbiota transplantation and anti-PD-1 therapy on treating colorectal cancer. Front Immunol. 2022;13:874922.","journal-title":"Front Immunol"},{"key":"2222_CR90","doi-asserted-by":"publisher","first-page":"106633","DOI":"10.1016\/j.phrs.2022.106633","volume":"188","author":"SL Zhang","year":"2023","unstructured":"Zhang SL, et al. Untangling determinants of gut microbiota and tumor immunologic status through a multi-omics approach in colorectal cancer. Pharmacol Res. 2023;188:106633.","journal-title":"Pharmacol Res"},{"issue":"10","key":"2222_CR91","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1016\/j.ccell.2024.08.019","volume":"42","author":"X Wang","year":"2024","unstructured":"Wang X, et al. Fusobacterium nucleatum facilitates anti-PD-1 therapy in microsatellite stable colorectal cancer. Cancer Cell. 2024;42(10):1729\u2013e17468.","journal-title":"Cancer Cell"},{"issue":"1","key":"2222_CR92","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/s41392-021-00795-x","volume":"6","author":"Y Gao","year":"2021","unstructured":"Gao Y, et al. Fusobacterium nucleatum enhances the efficacy of PD-L1 blockade in colorectal cancer. Signal Transduct Target Ther. 2021;6(1):398.","journal-title":"Signal Transduct Target Ther"},{"key":"2222_CR93","doi-asserted-by":"publisher","first-page":"102315","DOI":"10.1016\/j.eclinm.2023.102315","volume":"66","author":"W Zhao","year":"2023","unstructured":"Zhao W, et al. Fecal microbiota transplantation plus tislelizumab and fruquintinib in refractory microsatellite stable metastatic colorectal cancer: an open-label, single-arm, phase II trial (RENMIN-215). EClinicalMedicine. 2023;66:102315.","journal-title":"EClinicalMedicine"},{"issue":"11","key":"2222_CR94","doi-asserted-by":"publisher","first-page":"5351","DOI":"10.62347\/XKUJ3012","volume":"14","author":"W Zhao","year":"2024","unstructured":"Zhao W, et al. Updated outcomes and exploratory analysis of RENMIN-215: tislelizumab plus fruquintinib and fecal microbiota transplantation in refractory microsatellite stable metastatic colorectal cancer. Am J Cancer Res. 2024;14(11):5351\u201364.","journal-title":"Am J Cancer Res"},{"issue":"7","key":"2222_CR95","first-page":"e42347","volume":"15","author":"X Cheng","year":"2023","unstructured":"Cheng X, et al. Successful Treatment of pMMR MSS IVB Colorectal Cancer Using Anti-VEGF and Anti-PD-1 Therapy in Combination of Gut Microbiota Transplantation: A Case Report. Cureus. 2023;15(7):e42347.","journal-title":"Cureus"},{"key":"2222_CR96","doi-asserted-by":"crossref","unstructured":"Brusnic O, Onisor D. Fecal Microbiota Transplantation: Insights into Colon Carcinog Immune Regul. J Clin Med. 2024;13(21):6578.","DOI":"10.3390\/jcm13216578"},{"issue":"2","key":"2222_CR97","first-page":"e0006022","volume":"37","author":"A Yadegar","year":"2024","unstructured":"Yadegar A, Bar-Yoseph H, Monaghan TM. Fecal microbiota transplantation: Curr challenges future landscapes. Clin Microbiol Rev. 2024;37(2):e0006022.","journal-title":"Fecal microbiota transplantation: Curr challenges future landscapes"},{"key":"2222_CR98","doi-asserted-by":"publisher","first-page":"104967","DOI":"10.1016\/j.ebiom.2024.104967","volume":"100","author":"Y Yang","year":"2024","unstructured":"Yang Y, et al. Fecal microbiota transplantation: no longer cinderella in tumour immunotherapy. EBioMedicine. 2024;100:104967.","journal-title":"EBioMedicine"},{"issue":"2","key":"2222_CR99","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1053\/j.gastro.2020.10.057","volume":"160","author":"J Aron-Wisnewsky","year":"2021","unstructured":"Aron-Wisnewsky J, et al. Metabolism and Metabolic Disorders and the Microbiome: The Intestinal Microbiota Associated With Obesity, Lipid Metabolism, and Metabolic Health-Pathophysiology and Therapeutic Strategies. Gastroenterology. 2021;160(2):573\u201399.","journal-title":"Gastroenterology"},{"issue":"6","key":"2222_CR100","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1016\/j.cmet.2021.05.005","volume":"33","author":"NMJ Hanssen","year":"2021","unstructured":"Hanssen NMJ, de Vos WM, Nieuwdorp M. Fecal microbiota transplantation in human metabolic diseases: From a murky past to a bright future? Cell Metab. 2021;33(6):1098\u2013110.","journal-title":"Cell Metab"},{"key":"2222_CR101","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.jconrel.2024.05.002","volume":"370","author":"S Ma","year":"2024","unstructured":"Ma S, et al. Orally available dextran-aspirin nanomedicine modulates gut inflammation and microbiota homeostasis for primary colorectal cancer therapy. J Control Release. 2024;370:528\u201342.","journal-title":"J Control Release"},{"key":"2222_CR102","doi-asserted-by":"publisher","first-page":"1030745","DOI":"10.3389\/fimmu.2022.1030745","volume":"13","author":"X Hou","year":"2022","unstructured":"Hou X, et al. Effects of gut microbiota on immune responses and immunotherapy in colorectal cancer. Front Immunol. 2022;13:1030745.","journal-title":"Front Immunol"},{"issue":"12","key":"2222_CR103","first-page":"e71009","volume":"14","author":"M Dietz","year":"2025","unstructured":"Dietz M, Gates TJ, Sikdar R. Impeding Quorum Sens Among Intestinal Microbiota Impacts Metastatic Rate Colorectal Cancer. Cancer Med. 2025;14(12):e71009.","journal-title":"Impeding Quorum Sens Among Intestinal Microbiota Impacts Metastatic Rate Colorectal Cancer"},{"key":"2222_CR104","doi-asserted-by":"crossref","unstructured":"Chen J, Zhang P. Nitroreductase-instructed supramolecular assemblies for microbiome regulation to enhance colorectal cancer treatments. Sci Adv. 2022;8(45):eadd2789.","DOI":"10.1126\/sciadv.add2789"},{"issue":"52","key":"2222_CR105","doi-asserted-by":"publisher","first-page":"e1805007","DOI":"10.1002\/adma.201805007","volume":"30","author":"W Song","year":"2018","unstructured":"Song W, et al. Trapping of Lipopolysaccharide to Promote Immunotherapy against Colorectal Cancer and Attenuate Liver Metastasis. Adv Mater. 2018;30(52):e1805007.","journal-title":"Adv Mater"},{"issue":"2","key":"2222_CR106","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1093\/carcin\/bgaa100","volume":"42","author":"M Terasaki","year":"2021","unstructured":"Terasaki M, et al. Alteration of fecal microbiota by fucoxanthin results in prevention of colorectal cancer in AOM\/DSS mice. Carcinogenesis. 2021;42(2):210\u20139.","journal-title":"Carcinogenesis"},{"key":"2222_CR107","doi-asserted-by":"publisher","first-page":"153473542412803","DOI":"10.1177\/15347354241280390","volume":"23","author":"Z Gu","year":"2024","unstructured":"Gu Z, et al. Conventional Therapy Combined With Quxie Capsule Modulating Gut Microbiome in Metastatic Colorectal Cancer Patients With the Third or Above Line Setting: Result From an Investigator-Initiated, Open-Label, Single-Arm, Phase II Study. Integr Cancer Ther. 2024;23:15347354241280390.","journal-title":"Integr Cancer Ther"},{"key":"2222_CR108","doi-asserted-by":"publisher","first-page":"1096008","DOI":"10.3389\/fcimb.2023.1096008","volume":"13","author":"F Bu","year":"2023","unstructured":"Bu F, et al. Herbal medicine and its impact on the gut microbiota in colorectal cancer. Front Cell Infect Microbiol. 2023;13:1096008.","journal-title":"Front Cell Infect Microbiol"},{"key":"2222_CR109","doi-asserted-by":"crossref","unstructured":"Hu Y et al. Targeting the gut microbiota: a new strategy for colorectal cancer treatment. J Transl Med. 2024;22(1):915.","DOI":"10.1186\/s12967-024-05671-0"},{"issue":"6","key":"2222_CR110","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/s41419-019-1638-6","volume":"10","author":"J Lv","year":"2019","unstructured":"Lv J, et al. Gegen Qinlian decoction enhances the effect of PD-1 blockade in colorectal cancer with microsatellite stability by remodelling the gut microbiota and the tumour microenvironment. Cell Death Dis. 2019;10(6):415.","journal-title":"Cell Death Dis"},{"issue":"Pt A","key":"2222_CR111","doi-asserted-by":"publisher","first-page":"p116866","DOI":"10.1016\/j.jep.2023.116866","volume":"318","author":"J Wei","year":"2024","unstructured":"Wei J, et al. Echinacoside inhibits colorectal cancer metastasis via modulating the gut microbiota and suppressing the PI3K\/AKT signaling pathway. J Ethnopharmacol. 2024;318(Pt A):p116866.","journal-title":"J Ethnopharmacol"},{"key":"2222_CR112","doi-asserted-by":"publisher","first-page":"154217","DOI":"10.1016\/j.phymed.2022.154217","volume":"102","author":"S Yan","year":"2022","unstructured":"Yan S, et al. Berberine regulates short-chain fatty acid metabolism and alleviates the colitis-associated colorectal tumorigenesis through remodeling intestinal flora. Phytomedicine. 2022;102:154217.","journal-title":"Phytomedicine"},{"key":"2222_CR113","doi-asserted-by":"publisher","first-page":"117995","DOI":"10.1016\/j.jep.2024.117995","volume":"326","author":"X Wei","year":"2024","unstructured":"Wei X, et al. Anchang Yuyang Decoction inhibits experimental colitis-related carcinogenesis by regulating PPAR signaling pathway and affecting metabolic homeostasis of host and microbiota. J Ethnopharmacol. 2024;326:117995.","journal-title":"J Ethnopharmacol"},{"key":"2222_CR114","doi-asserted-by":"publisher","first-page":"156766","DOI":"10.1016\/j.phymed.2025.156766","volume":"142","author":"Z Zheng","year":"2025","unstructured":"Zheng Z, et al. KAJF alleviated colorectal cancer liver metastasis by reshaping the gut microbiota and inhibiting M2-like macrophage polarization. Phytomedicine. 2025;142:156766.","journal-title":"Phytomedicine"},{"key":"2222_CR115","doi-asserted-by":"publisher","first-page":"156833","DOI":"10.1016\/j.phymed.2025.156833","volume":"143","author":"X Liu","year":"2025","unstructured":"Liu X, et al. Sophocarpine suppresses MAPK-mediated inflammation by restoring gut microbiota in colorectal cancer. Phytomedicine. 2025;143:156833.","journal-title":"Phytomedicine"},{"key":"2222_CR116","doi-asserted-by":"crossref","unstructured":"Rong Y et al. Uncovering the Effects and Molecular Mechanisms of Shaoyao Decoction Against Colorectal Cancer Using Network Pharmacology Analysis Coupled With Experimental Validation and Gut Microbiota Analysis. Cancer Med. 2025;14(6):e70813.","DOI":"10.1002\/cam4.70813"},{"issue":"Pt 2","key":"2222_CR117","doi-asserted-by":"publisher","first-page":"144477","DOI":"10.1016\/j.ijbiomac.2025.144477","volume":"315","author":"L Chen","year":"2025","unstructured":"Chen L, et al. Poria cocos polysaccharides ameliorate AOM\/DSS-induced colorectal cancer in mice by remodeling intestinal microbiota composition and enhancing intestinal barrier function. Int J Biol Macromol. 2025;315(Pt 2):144477.","journal-title":"Int J Biol Macromol"},{"issue":"9","key":"2222_CR118","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1016\/j.jpha.2023.06.012","volume":"13","author":"H Yu","year":"2023","unstructured":"Yu H, et al. Gut microbiota-based pharmacokinetic-pharmacodynamic study and molecular mechanism of specnuezhenide in the treatment of colorectal cancer targeting carboxylesterase. J Pharm Anal. 2023;13(9):1024\u201340.","journal-title":"J Pharm Anal"},{"issue":"Pt 2","key":"2222_CR119","doi-asserted-by":"publisher","first-page":"143323","DOI":"10.1016\/j.ijbiomac.2025.143323","volume":"310","author":"G Zhang","year":"2025","unstructured":"Zhang G, et al. Chinese yam polysaccharide enhances anti-PD-1 immunotherapy in colorectal cancer through alterations in the gut microbiota and metabolites. Int J Biol Macromol. 2025;310(Pt 2):143323.","journal-title":"Int J Biol Macromol"},{"key":"2222_CR120","doi-asserted-by":"crossref","unstructured":"Nawab S et al. The Pathogenicity of Fusobacterium nucleatum Modulated by Dietary Fibers-A Possible Missing Link between the Dietary Composition and the Risk of Colorectal Cancer. Microorganisms, 2023;11(8):2004.","DOI":"10.3390\/microorganisms11082004"},{"issue":"2","key":"2222_CR121","doi-asserted-by":"publisher","first-page":"e2037341","DOI":"10.1001\/jamanetworkopen.2020.37341","volume":"4","author":"SK Veettil","year":"2021","unstructured":"Veettil SK, et al. Role of Diet in Colorectal Cancer Incidence: Umbrella Review of Meta-analyses of Prospective Observational Studies. JAMA Netw Open. 2021;4(2):e2037341.","journal-title":"JAMA Netw Open"},{"key":"2222_CR122","doi-asserted-by":"crossref","unstructured":"Taha HM, Slade AN, Schwartz B. A Case-Control Study Examining the Association of Fiber, Fruit, and Vegetable Intake and the Risk of Colorectal Cancer in a Palestinian Population. Int J Environ Res Public Health. 2022;19(12):7181.","DOI":"10.3390\/ijerph19127181"},{"issue":"7","key":"2222_CR123","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1053\/j.gastro.2024.07.040","volume":"167","author":"K Wang","year":"2024","unstructured":"Wang K, et al. An Empirical Dietary Pattern Associated With the Gut Microbial Features in Relation to Colorectal Cancer Risk. Gastroenterology. 2024;167(7):1371\u2013e13834.","journal-title":"Gastroenterology"},{"key":"2222_CR124","doi-asserted-by":"crossref","unstructured":"Thakur BK et al. Dietary fibre counters the oncogenic potential of colibactin-producing Escherichia coli in colorectal cancer. Nat Microbiol. 2025;10(4):855\u201370.","DOI":"10.1038\/s41564-025-01938-4"},{"key":"2222_CR125","doi-asserted-by":"publisher","first-page":"104873","DOI":"10.1016\/j.ebiom.2023.104873","volume":"98","author":"X Zhang","year":"2023","unstructured":"Zhang X, et al. Modulating a prebiotic food source influences inflammation and immune-regulating gut microbes and metabolites: insights from the BE GONE trial. EBioMedicine. 2023;98:104873.","journal-title":"EBioMedicine"},{"issue":"1","key":"2222_CR126","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/s40168-024-01900-2","volume":"12","author":"C De Filippo","year":"2024","unstructured":"De Filippo C, et al. Gut microbiota drives colon cancer risk associated with diet: a comparative analysis of meat-based and pesco-vegetarian diets. Microbiome. 2024;12(1):180.","journal-title":"Microbiome"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-026-02222-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-026-02222-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-026-02222-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:03:53Z","timestamp":1789430633000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-026-02222-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,28]]},"references-count":126,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2222"],"URL":"https:\/\/doi.org\/10.1007\/s10238-026-02222-3","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,28]]},"assertion":[{"value":"28 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Desalegn Abebaw, Adane Adugna, Bantayehu Addis Tegegne, Zigale Hibstu Teffera, Bantegzie Selabat, Yonatan Kindie, Melkamu Tilahun, Habtamu Belew, Temesgen Baylie, Getachew Mengistu, Mohammed Jemal, and Aytenew Atnaf have nothing to disclose.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"333"}}